Elliott Dunn

Elliott is currently an Analyst at Brandon Capital, Executive Director of a stealth therapeutic company, Director of Cadmus Animal Health and of TamoRx, and Board observer of MycRx. Prior to joining Brandon, Elliott project managed the research team at Blis Technologies Ltd before which he was a Commercialisation Analyst at Otago Innovation Ltd and a Scientific Officer in pharmacology at the University of Otago. After completing his PhD in 2018, Elliott chaired the Return On Science Biotech & Pharma and Otago Momentum Investment Committees, and conducted R&D for Upside Biotechnologies Ltd, which focused on developing a bioengineered solution for burns victims.
Elliott has a PhD in Stem Cell Biology from the University of Auckland, and a Masters in Immunology from the University of Otago.